Riskpilot← Back to searchSign inGet full accessKÄÄPÄ BioTech Oy
OYActiveY-tunnus 2917439-7Teilinummentie 2Support services to forestry · NACE 0240Est. 20187 employeeskaapabiotech.com
Revenue 2024
EUR 1,9M
+89% vs 2023
EBITDA margin
-21.0%
+37% vs 2023
Equity ratio
17.9%
Financial strength
Net profit 2024
EUR -914K
+1% vs 2023
| Revenue | EUR 1,9M | +89% |
| EBITDA | EUR -404K | +37% |
| Net profit | EUR -914K | +1% |
| Total assets | EUR 3,5M | +36% |
| Equity | EUR 619K | -39% |
| Employees | 7 | — |
Legal name
KÄÄPÄ BioTech Oy
Y-tunnus number
2917439-7
Legal form
Osakeyhtiö
NACE code
0240 · Support services to forestry
Founded
25. toukokuuta 2018
Share capital
EUR 2 941
Employees
7 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Metsätaloutta palveleva toiminta, Luontaistuotteiden tukkukauppa, Taimien kasvatus ja muu kasvien lisääminen, Muualla luokittelematon koulutus, Maataloutta palveleva toiminta, Muualla luokittelematon erikoistunut agentuuritoiminta, Kaikki laillinen liiketoiminta
Address
Teilinummentie 2
Email
contact@kaapabiotech.com
Website
kaapabiotech.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 572 | 847 | 930 | 1 018 | 1 927 |
| Staff expenses | −447 | −644 | −832 | −943 | −1 157 |
| EBITDA | 38 | −109 | −251 | −646 | −404 |
| Depreciation & amort. | −20 | −27 | −159 | −236 | −467 |
| EBIT | 18 | −136 | −409 | −882 | −871 |
| Net financials | −16 | −18 | −27 | −44 | −43 |
| Profit before tax | 2 | −154 | −437 | −926 | −914 |
| Tax | −0 | −2 | −0 | −0 | −0 |
| Net profit | 2 | −152 | −437 | −926 | −914 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 535 | 1 179 | 1 379 | 2 546 | 3 465 |
| Equity | 110 | 108 | 441 | 1 016 | 619 |
| Long-term debt | 300 | 351 | 649 | 1 090 | 1 651 |
| Short-term debt | 125 | 720 | 289 | 441 | 1 195 |
| Total debt | 425 | 1 071 | 939 | 1 531 | 2 846 |
EBITDA margin
-21.0%
This company
15.8%
Market median
-233% vs market
20202024
Equity ratio
17.9%
This company
38.2%
Market median
-53% vs market
20202024
Return on equity
-147.7%
This company
18.4%
Market median
-903% vs market
20202024
Net profit margin
-47.4%
This company
8.1%
Market median
-685% vs market
20202024
Asset turnover
0.56×
This company
1.12×
Market median
-50% vs market
20202024
Debt / equity
4.60×
This company
0.62×
Market median
-642% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
EM Chief Executive Officer | Chief Executive Officer | 2019 |
MM | Audit | 2025 |
AM Deputy auditor | Deputy auditor | 2025 |
| Former (1) | ||
HJ Chief Executive Officer | Chief Executive Officer | 2018 – 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairperson | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2023 | |
| Former (10) | ||
| Board of Directors | 2025 – 2025 | |
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2024 – 2025 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2018 – 2025 | |
| Board of Directors | 2021 – 2024 | |
| Board of Directors | 2019 – 2025 | |
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2018 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of KÄÄPÄ BioTech Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eric Michael Tweddale Puro | Chief Executive Officer | 0 companies |
| Maria Merita Kotiranta | Audit | 0 companies |
| Antti Mikael Taskinen | Deputy auditor | 0 companies |
| Henri Joonatan Lokki | Chief Executive Officer | 0 companies |
| Gali Olga Soria Artzi | Chairperson | 0 companies |
| Christine Celeste Fields | Board of Directors | 0 companies |
| Thomas Clay Kahler | Board of Directors | 0 companies |
| Mai Nygaard | Board of Directors | 0 companies |
| Christian Neuss | Board of Directors | 0 companies |
| Jarmo Juhani Jokinen | Board of Directors | 0 companies |
| Seppo Kalevi Riikonen | Board of Directors | 0 companies |
| Tuomo Tapani Rantanen | Board of Directors | 0 companies |
| Otso Mikael Mursula | Board of Directors | 0 companies |
| Clive Robert Spray | Board of Directors | 0 companies |
| Lorin von Longo-Liebenstein | Board of Directors | 0 companies |
| Javier Mansilla Martinez | Board of Directors | 0 companies |
| Sheldon Craig Baker | Board of Directors | 0 companies |